Nivea extends longevity offering with epigenetics eye serum featuring cryogenic technology

The skin care brand’s Cellular Epigenetics Age Rewind Eye Serum, fronted by singer Cheryl Cole, is designed to ‘give consumers more options to support their skin's long-term health’. It builds on the success of Nivea’s Cellular Epigenetics Age Rewind Face Serum

You need to be a subscriber to read this article.
Click here to find out more.

Nivea is strengthening its position in longevity beauty with a new eye serum that combines longevity science with cryogenic technology.

Cellular Epigenetics Age Rewind Eye Serum contains the Beiersdorf-owned skin care brand’s patented active epigenetics ingredient Epicelline, which claims to deliver visible age reversal by working at the cellular level, with cryogenic technology to rejuvenate. 

It is fronted by Brand Ambassador and Girls Aloud singer Cheryl Cole, who for the campaign has been shot on a glacier delivering the tagline ‘Life's About to Get Cold’ – a playful nod to the band’s song ‘Life Got Cold’.


Tickets are now available for the 25th anniversary of the Pure Beauty Awards, taking place on 15 October 2026 at the Grosvenor House Hotel in London, UK. Join the beauty industry for an evening of recognition and celebration as this year’s winners are revealed. Click here to secure your place. 


The new eye serum builds on the success of Nivea’s Cellular Epigenetics Age Rewind Face Serum, which launched last year and focused on precision anti-ageing powered by longevity science.

"We are seeing growing consumer interest in not just reversing [the] signs of ageing but also preventing them,” Andrew Rawle, Northern Europe Marketing Director at Nivea, told Cosmetics Business

“This is why we wanted to extend our longevity offering beyond just one serum in this area – to give consumers more options to

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.
  3. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like